Jefferies upgraded Instil Bio (TIL) to Buy from Hold with a price target of $52, up from $11. The firm sees significant upside for Instil Bio as its SYN2510 is the third U.S. asset with a global trial planned in 2025. Meanwhile, the stock is currently trading at cash, the analyst tells investors in a research note. The firm says SYN2510 is an early mover in the race and there is upside on both clinical data updates in the space and business development interests in the PD-(L)1xVEGF class drug class.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TIL:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue